RecruitingPHASE1, PHASE2NCT07053488
CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection
Studying Pediatric hepatocellular carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
- Intervention
- Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver(biological)
- Enrollment
- 90 enrolled
- Eligibility
- 16-85 years · All sexes
- Timeline
- 2025 – 2028
Study locations (1)
- Peking University Health Science Center (PKUHSC), Beijing, Changping, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07053488 on ClinicalTrials.govOther trials for Pediatric hepatocellular carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07328009A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular CarcinomaFudan University
- RECRUITINGNCT07295340Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC DetectionWest China Hospital
- RECRUITINGPHASE1NCT07364357A Phase I Study of CREPT-618 in Locally Advanced HCCCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGPHASE4NCT06717919HOPE Against Cancer Recurrence in HCCPhilipp Dutkowski
- RECRUITINGNCT07173868FDG PET-CT in Advanced Breast CancerSamsung Medical Center
- RECRUITINGNANCT06899152HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver CancerMontefiore Medical Center
- RECRUITINGNANCT06934018Effect of Surgical Margin Width on Recurrence and Survival in Patients With Hepatic Oligometastasis of Colorectal CancerFudan University
- RECRUITINGPHASE3NCT06900543Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphereChengdu New Radiomedicine Technology Co. LTD.